Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Crushed vs Whole Epclusa in HCV
NCT03389061Phase 4Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of velpatasvir in hepatitis C (HCV) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Area Under the Curve at 24 hours and Maximum Plasma Concentration at 24 hours. Planned start Apr 2018; status: withdrawn.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03389061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389061.